A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis
Phase of Trial: Phase III
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Ixekizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms IXORA-P
- Sponsors Eli Lilly
- 07 Sep 2017 Status changed from active, no longer recruiting to completed.
- 01 Sep 2017 This trial was completed in Germany (end date: 2017-04-20), according to European Clinical Trials Database.
- 21 Jul 2017 Trial has been completed in Poland.